Literature DB >> 24468658

Chronic migraine with and without medication overuse: experience in a hospital series of 434 patients.

E Rojo1, M I Pedraza2, I Muñoz2, P Mulero2, M Ruiz2, C de la Cruz2, J Barón2, C Rodríguez2, S Herrero2, A L Guerrero2.   

Abstract

INTRODUCTION: Chronic migraine (CM) is a complication of episodic migraine, favored by risk factors as medication overuse (MO). We intend to compare demographic and clinic characteristics of a series of CM patients, with and without MO.
METHODS: The study included patients with CM (2006 revised criteria) attended in a headache outpatient office located in a tertiary hospital between January 2008 and May 2012. We recorded demographic characteristics, age at migraine onset, time from onset, previous use of symptomatic or preventive therapy, and headache impact measured with six-item headache impact test (HIT-6).
RESULTS: A total of 434 patients (357 women, 77 men) were diagnosed with CM out of the 1868 (23.2%) that attended our clinic. Of these, 258 (72.2%) fulfilled criteria of MO, and 59.8% of those with MO, and 41.1% of cases without MO had previously received preventative treatment (P<.001). Age at onset of migraine was lower in MO patients (21.2±10.1 vs 23.8±12.5 years, P=.02) and time from onset to headache clinic consultation was higher in MO cases (23.8±14.1 vs 18.3±14.8 years, P<.001). We found no difference between both groups in average HIT-6 score and the percentage of patients with a HIT-6 score over 55.
CONCLUSIONS: CM, with or without MO, is a burdensome group of patients in our headache clinic. Patients with MO are referred later and have more frequently received preventive treatments.
Copyright © 2013 Sociedad Española de Neurología. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Chronic migraine; Epidemiology; Epidemiología; Headache Impact Test-6; Medication overuse; Migraine; Migraña; Migraña crónica; Preventive treatments; Preventivos; Uso excesivo de medicación

Mesh:

Year:  2014        PMID: 24468658     DOI: 10.1016/j.nrl.2013.12.003

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  4 in total

1.  OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm.

Authors:  María Isabel Pedraza; Carolina de la Cruz; Marina Ruiz; Luis López-Mesonero; Elena Martínez; Mercedes de Lera; Ángel Luis Guerrero
Journal:  Springerplus       Date:  2015-04-13

2.  Manual therapy for chronic migraine: a pragmatic randomised controlled trial study protocol.

Authors:  Jim Odell; Carol Clark; Adrian Hunnisett; Osman Hassan Ahmed; Jonathan Branney
Journal:  Chiropr Man Therap       Date:  2019-03-27

3.  Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.

Authors:  Antonio Santoro; Andrea Fontana; Anna M Miscio; Michele M Zarrelli; Massimiliano Copetti; Maurizio A Leone
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

4.  Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire.

Authors:  Alberto Raggi; Venusia Covelli; Erika Guastafierro; Matilde Leonardi; Chiara Scaratti; Licia Grazzi; Marco Bartolini; Giovanna Viticchi; Sabina Cevoli; Giulia Pierangeli; Gioacchino Tedeschi; Antonio Russo; Piero Barbanti; Cinzia Aurilia; Carlo Lovati; Luca Giani; Fabio Frediani; Paola Di Fiore; Francesco Bono; Laura Rapisarda; Domenico D'Amico
Journal:  J Headache Pain       Date:  2018-09-10       Impact factor: 7.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.